Search Results
Sep 10, 2026, 08:00 ET Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Aug 25, 2026, 10:31 ET Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
market is also benefiting from the introduction of novel therapies, including Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others, and innovative drug delivery approaches that address unmet clinical needs.LAS
More news about: DelveInsight Business Research, LLP
Aug 04, 2026, 08:00 ET Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Aug 03, 2026, 08:00 ET Lipocine Appoints Michael J. Grissinger to Board of Directors
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Jun 04, 2026, 08:00 ET Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
May 19, 2026, 08:00 ET Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
May 18, 2026, 08:00 ET Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
May 07, 2026, 16:05 ET Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Apr 02, 2026, 08:00 ET Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2202 for treatment of treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148
More news about: Lipocine Inc.
Mar 10, 2026, 08:00 ET Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Feb 18, 2026, 08:00 ET Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted
More news about: Lipocine Inc.
Jan 20, 2026, 08:00 ET Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2202 for treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved
More news about: Lipocine Inc.
Jan 12, 2026, 08:00 ET Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2202 for treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved
More news about: Lipocine Inc.
Dec 16, 2025, 08:00 ET Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2202 for treatment of treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid
More news about: Lipocine Inc.
Nov 18, 2025, 08:00 ET Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2202 for treatment of treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148
More news about: Lipocine Inc.
Nov 06, 2025, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
including with respect to LPCN 1154, LPCN 2101, and LPCN 2401, our Phase 3 safety and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, the potential Phase 2 proof-of-concept studies for LPCN 2101 and LPCN 2401, potential partnering
More news about: Lipocine Inc.
Nov 04, 2025, 08:00 ET Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
As previously disclosed, LPCN 2401 and LPCN 2401+E were shown to increase lean mass, and reduce fat mass and fat to lean mass ratio, at 20 weeks and 36 weeks compared to placebo. Treatment with LPCN 2401 and LPCN 2401+E resulted in rapid beneficial effects
More news about: Lipocine Inc.
Sep 30, 2025, 08:00 ET Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen
More news about: Lipocine Inc.